8 recruiting, 2 active not recruiting, 1 available, 1 completed. 9 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 5, Active not recruiting 2, Completed 1, Withdrawn 1 |
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Recruiting 2 |
Follow tebentafusp: new trials by email Literature Review of tebentafusp trials Research Report on tebentafusp
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma Melphalan/HDS (Percutaneous Hepatic Perfusion), Tebentafusp - Metastatic Uveal Melanoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 18 | 2025-12-31 | 2026-03-31 |
| A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma Physician's Choice, Tebentafusp - HLA-A*0201 Positive Cells Present, Clear Cell Sarcoma (CCS) | Phase 2 | Recruiting | Sarcoma Alliance for Research through Collaboration | 47 | 2025-10-22 | 2026-10-02 |
| Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma Tebentafusp - Uveal Melanoma | Phase 2 | Recruiting | Diwakar Davar | 44 | 2025-08-18 | 2026-09-09 |
| Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma Tebentafusp - Mestastatic Uveal Melanoma | Phase 2 | Recruiting | Grupo Español Multidisciplinar de Melanoma | 19 | 2025-07-18 | 2026-09-15 |
| Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization - Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver | Phase 2 | Recruiting | University of Miami | 30 | 2025-02-14 | 2026-02-23 |
| Adjuvant Tebentafusp in High Risk Ocular Melanoma Tebentafusp - Uveal Melanoma | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 290 | 2024-11-11 | 2026-06-30 |
| DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors DCSZ11, Pembrolizumab, Doxorubicin - Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | DynamiCure Biotechnology | 320 | 2023-06-28 | 2025-06-26 |
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice - Advanced Melanoma | Phase 3 | Recruiting | Immunocore Ltd | 540 | 2022-12-19 | 2026-02-25 |
| Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma Tebentafusp - Melanoma (Skin), Melanoma, Uveal | Phase 2 | Active not recruiting | University of Oxford | 850 | 2022-07-25 | 2025-07-17 |
| Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy - Select Advanced Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | Immunocore Ltd | 410 | 2020-02-25 | 2026-03-06 |
| A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma IMCgp100 - Uveal Melanoma | Phase 1 / Phase 2 | Completed | Immunocore Ltd | 146 | 2016-02-29 | 2023-03-21 |
| Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma Tebentafusp (IMCgp100) - Malignant Melanoma | Phase 1 / Phase 2 | Withdrawn | Immunocore Ltd | 2015-11-01 | 2024-07-24 | |
| A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp Tebentafusp - Uveal Melanoma | Available | Immunocore Ltd | 2022-01-21 |
Uveal Melanoma (7) · Melanoma (6) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Neoplasm Metastasis (1) · Nevus, Blue (1) · Sarcoma (1) · Sarcoma, Clear Cell (1)
Immunocore Ltd (5) · Diwakar Davar (1) · DynamiCure Biotechnology (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Grupo Español Multidisciplinar de Melanoma (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Sarcoma Alliance for Research through Collaboration (1) · University of Miami (1) · University of Oxford (1)
United States (10) · United Kingdom (6) · Germany (5) · Spain (5) · Australia (3) · Belgium (3) · Canada (3) · France (3) · Poland (3) · Austria (2) · Italy (2) · Netherlands (2) · South Korea (2) · Switzerland (2) · Brazil (1)
Diwakar Davar, MD, PhD (1) · Jonathan Zager, MD, FACS (1) · Josep Maria Piulats, M.D., Ph.D. (1) · Lynn Feun, MD (1) · Mark Middleton (1) · Paul Nathan (1) · Richard D. Carvajal (1) · Serge Leyvraz (1)
2019 (1), 2023 (1)